The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) joint work plan (Cell and Gene Therapy Catapult – Regulatory Round-up – April 2022)
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint work plan until 2023.
See also, EMA and the EUnetHTA 21 consortium set priorities for their collaboration on the European Medicines Agency website.
See all of Catapult’s Regulatory Round-up for April 2022 here. Published on the 29th of April 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (3 août 2022). The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) joint work plan (Cell and Gene Therapy Catapult – Regulatory Round-up – April 2022). ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/o61v
